



# Company Presentation

June 2014

# Velocity's Organizational Snapshot

---


- Founded 2011
- South San Francisco, CA
- World-class pharmaceutical development team
- New model for efficient development to human Proof-of-Concept

# Our Investment Strategy


---

- Lead investor CMEA Capital
- Acquire promising drug candidates from third parties (pharma, biotech, academia)
- Single team manages development of the entire portfolio of drug candidates
- Develop to key value inflection: clinical Proof-of-Concept (generally phase IIa)
- Short holding period: average of 3 years for each drug
- Velocity will commit \$5-15M per project to fund clinical development to Proof-of-Concept
- Exit successful drug programs at Proof-of-Concept via sale to pharma

# Velocity Structure



# Example Capital Structure



# Velocity Pipeline

Indications	Preclinical	Phase I	Phase II
<b>VPD-737</b> <u>NK1 antagonist for Chronic Pruritus</u>			
<b>VPD-107</b> <u>Long-acting GLP1/ Glucagon dual agonist Type2 Diabetes</u>			
<b>VPH-380</b> <u>Pulmonary Disease (Undisclosed)</u>			
<b>VPD-210</b> <u>Protein replacement for Orphan Disease (Undisclosed)</u>			